EcoDrugPlus

Gamma-Aminobutyric Acid (Gaba) A Receptor, Delta

Ensembl ID : ENSXETG00000016013
Gene Symbol: GABRD
5 View Cross-references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Gamma 2

Ensembl ID : ENSXETG00000023224
Gene Symbol: GABRG2
4 Enzyme and pathways 5 View Cross-references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Gamma 3

Ensembl ID : ENSXETG00000041217
Gene Symbol: GABRG3
4 Enzyme and pathways 5 View Cross-references
293 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) A Receptor, Pi

Ensembl ID : ENSXETG00000018298
Gene Symbol: GABRP
5 View Cross-references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) B Receptor, 1

Ensembl ID : ENSXETG00000020346
Gene Symbol: GABBR1
17 Enzyme and pathways 5 View Cross-references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSXETG00000018917
Gene Symbol: GABBR2
17 Enzyme and pathways 5 View Cross-references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSXETG00000046829
Gene Symbol: GLP1R
11 Enzyme and pathways 4 View Cross-references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucagon Receptor

Ensembl ID : ENSXETG00000005421
Gene Symbol: GCGR
11 Enzyme and pathways 5 View Cross-references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucagon-Like Peptide 2 Receptor

Ensembl ID : ENSXETG00000049286
Gene Symbol: GLP2R
7 Enzyme and pathways 5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucokinase (Hexokinase 4)

Ensembl ID : ENSXETG00000019003
Gene Symbol: GCK
5 Enzyme and pathways 5 View Cross-references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glucosylceramidase Beta 1

Ensembl ID : ENSXETG00000045974
Gene Symbol: GBA1
4 Enzyme and pathways 4 View Cross-references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSXETG00000022933
Gene Symbol: GRIN1
13 Enzyme and pathways 5 View Cross-references
279 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).